anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
α-1 Antitrypsin (AAT) is an acute-phase reactant with immunomodulatory properties that mainly inhibits neutrophil elastase. Low serum levels cause AAT deficiency (AATD), an underdiagnosed condition that predisposes to pulmonary and hepatic diseases. The SERPINA1 gene, which encodes AAT, contains >500 variants. PI∗Z and PI∗S alleles are the most diagnosed causes of AATD, but the role of the SERPINA1 haplotypes in AAT function remains unknown. SERPINA1 gene was PCR amplified from 94 patients with asthma, using primers with tails for indexing. Sequencing libraries were loaded into a MinION-Mk1C, and MinKNOW was used for basecalling and demultiplexing. Nanofilt and Minimap2 were used for filtering and mapping/alignment. Variant calling/phasing were performed with PEPPER-Margin-DeepVariant. SERPINA1 gene was 100% covered for all samples, with a minimum sequencing depth of 500×. A total of 75 single-nucleotide variants (SNVs) and 4 insertions/deletions were detected, with 45 and 2 of them highly polymorphic (minor allele frequency >0.1), respectively. Nine of the SNVs showed differences in allele frequencies when compared with the overall Spanish population. More than 90% of heterozygous SNVs were phased, yielding 91 and 58 different haplotypes for each SERPINA1 amplified region. Haplotype-based linkage disequilibrium analysis suggests that a recombination hotspot could generate variation in the SERPINA1 gene. The proposed workflow enables haplotype-aware genotyping of the SERPINA1 gene by nanopore sequencing, which will allow the development of novel AATD diagnostic strategies.
Cipla BioTec, a pharmaceutical company (company developing drugs), is developing its own formulation of bevacizumab called CBT124 which is similar to Avastin(Registered Trademark). The formulation is, intended for intravenous (into a vein) administration for the treatment of certain cancers. CBT124 is also a type of monoclonal antibody with a proposed biological activity similar to bevacizumab. Research on CBT124 indicates that it should act the same as Avastin(Registered Trademark) in the body. It is expected that CBT124 will provide all the clinical advantages of the marketed drug Avastin(Registered Trademark). The main purpose of this study is to test that whether CBT124 behaves the same in the human body as Avastin(Registered Trademark) i.e. produce the same amount/concentration of drug in the blood as the EU and USA marketed drug, Avastin(Registered Trademark). This is called a 'biosimilar' study. The study will compare the safety, tolerability, pharmacokinetics (PK) (the levels of drug in the blood), pharmacodynamics (PD) (what the drug does to the body) and immunogenicity (body's immune (body's defense system) response) of the 3 drugs when given intravenously (into a vein) to healthy male participants: new drug called CBT124, marketed drug Avastin(Registered Trademark) approved in United States (US), marketed drug Avastin(Registered Trademark) approved in European Union (EU). The results will be compared to see if these drugs behave the same and are therefore equivalent. In order to measure this, blood samples will be collected after treatment has been given and the amount of drug in the blood measured at specific times. In addition, the study will also compare and analyse the effect the drug has on your immune system from blood samples. Safety and tolerability of both drugs will also be monitored and compared.
The aerobic exercise group will cycle on an ergometer bicycle 2-3 times a week for 12 weeks on moderate loading. The loading will be controlled by a heart rate monitor and is defined as 85% of maximal heart rate.
1,246,315. Cytostatic preparations. SANDOZ Ltd. 18 Oct., 1968 [20 Oct., 1967; 28 Feb., 1968], No. 49497/68. Heading A5B. Cytostatic preparations for the treatment of malignant tumours comprise a cytostatic component comprising a hydrazide derivative of podophyllinic acid (especially the ethyl hydrazide) and a plasmakinin component comprising kallidin, methionyl hallidin or bradykinin. The preparation may comprise from 400 to 1600 mg. of the hydrazide derivative of podophyllinic acid and from 5 to 200γ of the plasmakinin component. The preparation may be administered intra-arterially e.g. by infusion of aqueous solutions containing NaCl or glucose. The preparation may be in the form of a pack comprising the two components, preferably contained in separate ampoules so that the components may either be separately administered simultaneously or may first be admixed and administered.
The invention discloses patrinia scabiosaefolia primitive hard capsules, soft capsules, medicinal granules, oral liquid and a health protection tea, which have the effects of relieving heat for detoxication, promoting blood circulation to dispel blood stasis, removing food stagnancy to help digestion, and relaxing the bowels and promoting urination. The patrinia scabiosaefolia primitive hard capsules have the functions of reducing blood sugar, blood pressure, blood fat, plasma cholesterol, triglyceride and blood viscosity, resisting atherosclerosis, softening and expanding cardiac and cerebral blood vessels, and improving cardiac muscle ischemia. Flowers, seeds and roots of patrinia scabiosaefolia have the effects of easing mind and improving sleeping. By eating and drinking patrinia scabiosaefolia products for a long time, hypertension, hyperlipemia, hyperglycemia and coronary diseases can be prevented and treated, and the disease incidence of 1-2 type diabetes can be reduced. A lozenge of the patrinia scabiosaefolia has an effect of treating canker sore, pharyngitis, iaryngopharyngitis and all kinds of toothaches. A patrinia scabiosaefolia extract has the effects of arresting bleeding, relieving pain and relieving itching to skin traumas. The patrinia scabiosaefolia primitive hard capsules have a special effect of treating rhinitis, herpes, eczema, heat rash (miliaria), allergic dermatitis, skin ulcers, scabies, cold injuries, burn, scald and skin ulcers caused by diabetic complications.
All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation. One week following surgery, subjects randomized to the BFR group will begin combining BFR with all lower extremity strengthening exercises supervised in clinic up to 3 times per week for 12 weeks.
Approximately half of persons with multiple sclerosis (MS) develop memory decline, which makes it difficult to maintain gainful employment, manage a household, and lead a fully-engaged social life. There are currently no validated symptomatic treatments for memory deficits in persons with MS. The study team will perform a fourteen week double-blind phase-two crossover randomized controlled trial (RCT) of atomoxetine (80mg qd, six weeks) versus placebo (six weeks) to improve memory in MS patients with documented memory impairment (two-week washout between phases). Atomoxetine is a non-stimulant selective norepinephrine reuptake inhibitor FDA-approved to treat cognitive-behavioral symptoms of attention deficit / hyperactivity disorder (ADHD; Strattera, Eli Lilly). Pre-clinical evidence suggests that atomoxetine may also improve memory by targeting brain mechanisms responsible for memory function (norepinephrine in the hippocampus). Twenty-four MS patients demonstrating objective memory impairment on neuropsychological screening tests will be randomly assigned to once-daily orally-administered atomoxetine or identically-encapsulated placebo. After a two-week washout period, patients will be switched to the opposite condition. The RCT will be performed at the Corinne Goldsmith Dickinson Center for MS at the Icahn School of Medicine at Mount Sinai. Baseline and follow-up evaluations will assess change in objective memory function (Primary Outcome), as well as Secondary Outcomes of patient-reported memory change, additional objective measures of memory function, and a measure of speeded symbol-digit coding (the most widely-used test of cognition in persons with MS). Tertiary / Other Outcomes examine sustained attention, processing speed, working memory, fatigue, mood, manual dexterity, and walking speed. The researchers predict that atomoxetine will lead to significantly greater improvements in Primary and Secondary memory outcomes relative to placebo. Consistent with the ADHD literature, there may be additional benefits of atomoxetine versus placebo on measures of attention, processing speed, and working memory. Results of this phase 2 trial will inform decisions / planning for a possible phase 3 trial, which may ultimately support the use of non-stimulant, once-daily atomoxetine as a memory treatment option for MS patients.
BACKGROUND: Despite regional brain structural changes having been reported in patients with chronic low back pain (CLBP), the topological properties of structural covariance networks (SCNs), which refer to the organization of the SCNs, remain unclear. This study applied graph theoretical analysis to explore the alterations of the topological properties of SCNs, aiming to comprehend the integration and separation of SCNs in patients with CLBP.
METHODS: A total of 38 patients with CLBP and 38 healthy controls (HCs), balanced for age and sex, were scanned using three-dimensional T1-weighted magnetic resonance imaging. The cortical thickness was extracted from 68 brain regions, according to the Desikan-Killiany atlas, and used to reconstruct the SCNs. Subsequently, graph theoretical analysis was employed to evaluate the alterations of the topological properties in the SCNs of patients with CLBP.
RESULTS: In comparison to HCs, patients with CLBP had less cortical thickness in the left superior frontal cortex. Additionally, the cortical thickness of the left superior frontal cortex was negatively correlated with the Visual Analogue Scale scores of patients with CLBP. Furthermore, patients with CLBP, relative to HCs, exhibited lower global efficiency and small-worldness, as well as a longer characteristic path length. This indicates a decline in the brain's capacity to transmit and process information, potentially impacting the processing of pain signals in patients with CLBP and contributing to the development of CLBP. In contrast, there were no significant differences in the clustering coefficient, local efficiency, nodal efficiency, nodal betweenness centrality, or nodal degree between the two groups.
CONCLUSIONS: From the regional cortical thickness to the complex brain network level, our study demonstrated changes in the cortical thickness and topological properties of the SCNs in patients with CLBP, thus aiding in a better understanding of the pathophysiological mechanisms of CLBP.
Participants receive pembrolizumab 200 mg Q3W plus cisplatin 60 mg/m\^2 Q3W by IV infusion plus TS-1 BID by continuous oral administration for 14 days, followed by a recovery period of 7 days. Study treatment will be started on Day 1 of each 3-week course, and will continue for up to \~3 years.
Cohorts of 3-6 patients each receive escalating doses of intraperitoneal recombinant human interleukin-12 (rhIL-12) administered weekly for 9 weeks. If a patient tolerates rhIL-12 and shows evidence of objective response or stable disease, patient may receive up to 9 additional weeks of treatment. Treatment continues in the absence of unacceptable toxicity or disease progression. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which no more than 1 of 6 patients experiences dose limiting toxicity.
A multifunctional self-contained system that wirelessly integrates actual sports equipment with a computer providing critical feedback to improve all aspects of a player's game, and also allows players to play an actual competitive real or visually simulated game or sports with one or more players. Therefore, an individual player may opt to play solo or practice to improve basic golfing skills and techniques. The system includes sport implements that include, but are not limited to, smart golf clubs, a golf ball receptacle and a golf club motion sensing device, all containing circuits with contact sensors and or motion sensors coupled with signal processing and radio frequency transmitter circuitry to wirelessly communicate game status and performance parameters to a remote receiver and computer. The computer then optionally displays important parameters such as proximity of a sports implement contact face to an object, the impact of a sports implement with a sports equipment item, wherein the contact force, contact time, impact location, face angle, spatial orientation of a sports implement in motion, and the subsequent energy, velocity, and trajectory of game projectile such as a golf ball. The sports implements can be further equipped with motion sensing devices, and its motion and swing trajectory is visually simulated on the computer display. Standard sport implements which include, but are not limited to, golf clubs may be retrofitted with the device sensors and associated electronic circuitry to convert such clubs into “smart clubs” for use with the system. The system employs specially developed computer software to process player performance data, control game play, communicate game information to players, generate and control visual simulations, and display player performance information.
Lung cancer complicated by follicular lymphoma has rarely been reported in the literature. A 69-year-old male with an abnormal shadow on a chest radiograph was referred to our hospital. A mass in the right lung was seen on chest computed tomography (CT). Positron emission tomography-CT showed fluorodeoxyglucose accumulation in the esophagus and multiple intra-abdominal lymph nodes, in addition to the right lung lesion. The lung lesion was diagnosed as a pulmonary adenocarcinoma after biopsy. Upper and lower gastrointestinal endoscopies did not reveal the presence of a tumor. Open lymph node biopsy was performed to determine the course of treatment, leading to a diagnosis of follicular lymphoma. The patient finally underwent radical resection for lung cancer; the follicular lymphoma was judged to be low-grade and was followed up. When complications involving other organs are detected during systemic examination of a patient with lung cancer, it is necessary to distinguish between metastasis to other organs and complications of other malignant diseases, as this will greatly influence the treatment strategy.
There is considerable variation in the half-life of testosterone as reported in the literature, ranging from ten to 100 minutes.

Testosterone is metabolized to various 17-keto steroids through two different pathways. The major active metabolites of testosterone are estradiol and DHT. Testosterone is metabolized to DHT by steroid 5α-reductase located in the skin, liver, and the urogenital tract of the male. DHT binds with greater affinity to SHBG than does testosterone. In many tissues, the activity of testosterone depends on its reduction to DHT, which binds to cytosol receptor proteins. The steroid-receptor complex is transported to the nucleus where it initiates transcription and cellular changes related to androgen action. In reproductive tissues, DHT is further metabolized to 3α and 3β androstanediol. Inactivation of testosterone occurs primarily in the liver.

DHT concentrations increased in parallel with testosterone concentrations during Testim® treatment. After 90 days of treatment, mean DHT concentrations remained generally within the normal range for Testim®-treated subjects.
PURPOSE: To obtain a therapeutic agent containing an ataractic agent and a benzodiazepine having sedative and hypnotic actions as active components and effective for the treatment of severe fit of abdominal pain of healthy child, celialgia having symptom of crying by excitation, tooth eruption pain, etc. CONSTITUTION: This agent contains an ataractic agent and a benzodiazepine having sedative and hypnotic actions as active components. The ataractic agent is a compound of the formula [R<1> is a 1-6C alkyl, a 1-6C hydroxyalkyl, a hydroxy-(1-6C alkoxy)-(1-6C alkyl), etc.; R<2> and R<3> are each H, a halogen or a 1-6C alkyl] (e.g. hydroxyzimbamoate) or its salt. The benzodiazepine is preferably diazepam and the molar ratio of the hydroxyzimbamoate to the diazepam is preferably about 0.1-0.5.
Provided are methods of subcutaneous administration of anti-CD38 monoclonal antibodies, such as daratumumab. Also provided are methods for the treatment of autoimmune diseases with subcutaneously administered anti-CD38 monoclonal antibodies. A corticosteroid is optionally administered prior to subcutaneous administration of the anti-CD38 antibody to prevent and/or reduce systemic injection related side effects.Provided are methods of subcutaneous administration of anti-CD38 monoclonal antibodies, such as daratumumab. Also provided are methods for the treatment of autoimmune diseases with subcutaneously administered anti-CD38 monoclonal antibodies. A corticosteroid is optionally administered prior to subcutaneous administration of the anti-CD38 antibody to prevent and/or reduce systemic injection related side effects. A robotic animal puzzle is assembled from flat board pieces. The robotic animal includes a head portion. The head portion includes a neck group, a torso portion, including a holder 15 for an optional battery, multiple leg portions, and a tail portion. Those pieces and groups are connected using either interlocking mechanisms or flexible linkages to form the robotic animal-shaped puzzle. Movement and gestures may be controlled by an externally connected processor powered by an on-board battery pack. A pull and drag mechanism is provided to conveniently tune the center of mass. Slots allow the screw that connects the battery holder to slide.
1436355 Preparation of particulate materials P SPEISER 4 Dec 1973 [4 Dec 1972] 56045/73 Heading C3R [Also in Division A5] Particles having a diameter less than 200 nanometres (referred to as "nanocapsules") are made by forming a dispersion with substantially mutually insoluble aqueous and hydrophobic phases in which the particles of disperse phase are less than 200 nanometres in diameter and contain both a polymerizable monomer substantially insoluble in the continuous phase and an active material, and causing polymerization of the monomer without substantially decomposing the active material. The product is said to be composed of particles of various structures including a "microcapsular" structure and forms in which the active material is held within a molecular lattice of the polymer. It may be made by forming an aqueous phase in which the active material is dissolved or colloidally disposed, dispersing it in an immiscible non-aqueous phase, e.g. n-hexane, adding a water-insoluble monomer, e.g. acrylamide or N,N<SP>1</SP>-methylene-bis-acrylamide and causing polymerization thereof, e.g. by irradiation. A suitable surface active agent may be added to the continuous phase to assist in dispersing the disperse phase the process being carried out using either an aqueous (as above) or non-aqueous disperse phase. In the latter case, suitable monomers for use are acrylic and methacrylic acids. The particles may subsequently be separated, e.g. by filtration, centrifugation or distillation of the liquid phases. Specific examples relate to the preparation of particles containing diphtheria or tetanus toxoid, human gamma globulin, urease and riboflavin-5<SP>1</SP>-sodium phosphate.
Rotational atherectomy (RA) prior to angioplasty is the reference treatment for highly calcified atherosclerotic coronary lesions. It aims at fragmenting calcium deposits into microscopic particulates to allow less hazardous coronary revascularization and stenting. The main drawback associated with the procedure is the subsequent enhancement of platelet aggregation which promotes the distal embolization of micro-thrombi and atherosclerotic fragments. In order to limit these complications, a double antiplatelet therapy is required (generally Clopidogrel + Aspirin) when RA procedures are performed. Clopidogrel inhibits the protein P2Y12 which is a cornerstone in platelet aggregation. It is characterized by a slow and variable transformation of a prodrug into an active metabolite and by a remaining risk of thrombosis and myocardial infarction. Ticagrelor is a new antiplatelet agent that provides faster and greater P2Y12 inhibition than Clopidogrel. It is currently indicated to reduce risk of cardiovascular events in patients hospitalized for coronary revascularization after an acute coronary syndrome. Ticagrelor has never been evaluated so far in stable coronary patients treated with rotational atherectomy prior to angioplasty.
Early ACL reconstruction is performed within 12 weeks after ACL injury and is followed by rehabilitation led by a physiotherapist. ACL surgical technique and rehabilitation is pragmatic according to the routines at the including centre.
Prior to unicompartmental knee arthroplasty (UKA), corticosteroid injections (CSI) are a common nonoperative treatment for arthritis. It is unclear whether CSI prior to UKA impacts the likelihood of postoperative infection. This study sought to determine if there is a time- and/or dose-dependent relationship between preoperative CSI and postoperative infection. An administrative claims database was queried for patients undergoing UKA with more than 1 year of pre-enrollment and follow-up. Of 31,676 patients with a UKA who met enrollment criteria, 8,628 patients had a CSI 0 to 3 months prior to surgery, 111 had a CSI 3 to 12 months prior to surgery, and 22,937 never received an injection. Overall, 246 postoperative deep infections were reported (0.8%). Time-dependent and dose-dependent relationships were modeled using multivariable logistic regressions. Postoperative deep infections occurred in 64 patients with CSI 0 to 3 months prior to surgery (0.7%), compared with 0 patients with CSI 3 to 12 months before surgery (0.0%) and 182 controls (0.8%, p = 0.58). CSI within 1 month prior to UKA was not statistically associated with postoperative infection (p = 0.66). Two or more CSI within 3 months prior to UKA were associated with a twofold elevated odds of infection, compared with receiving a single injection (odds ratio [OR]: 2.08, p = 0.03). Univariable predictors of infection included younger age, increasing Charlson Comorbidity Index, smoking, asthma, chronic obstructive pulmonary disease, chronic kidney disease, diabetes, liver disease, and obesity. Multivariable analysis controlling for these characteristics elicited no relationship between recent CSI administration and postoperative infection. CSI within 3 months of surgery (1.5%) or 3 to 12 months (1.8%) were associated with increased conversion to total knee arthroplasty (TKA) compared with those who did not receive an injection (1.1%, p = 0.01), although TKA for indication of periprosthetic joint infection was not statistically different (p = 0.72). Preoperative CSI within 3 months of UKA is not associated with postoperative infection, although significant medical comorbidity does show an association. Preoperative CSI is associated with increased conversion from UKA to TKA for noninfectious indications.
The activity will be delivered to a group of maximum 5 neighbouring households at the time. Hygiene promoters will bring some food oil and ask participants to cover their hands in food oil. They will then ask the participants to cover their hands in turmeric powder. The participants will then be asked to wash their hands with water only. This will have little effect on the cleanliness of their hands. Then participants will be given a bar of soap. The participants will then be asked to wash their hands again. This will leave their hands nice comfortable and clean. They will experience the comfort of clean hands and the activity hope to increase regular handwashing.